|
57 Products |
| 57 Products |
|
190 Diseases |  |
11232 News |  |
| «12...9899100101102103104105106107108109110» |
- |||| Biomarker, Trial completion: Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 17, 2013
P4, N=531, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed
- |||||| Mayzent (siponimod) / Novartis
Enrollment open: Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) (clinicaltrials.gov) - Jan 15, 2013
P3, N=1530, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Tysabri (natalizumab) / Biogen, Royalty
Enrollment change: TOFIINGO: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (clinicaltrials.gov) - Jan 14, 2013
P4, N=158, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=600 --> 158
- |||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: TOFIINGO: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (clinicaltrials.gov) - Jan 14, 2013
P4, N=158, Completed, Sponsor: Novartis Pharmaceuticals
N=600 --> 158 Active, not recruiting --> Completed
- | iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
New P2 trial: A Phase 2 Study of ASONEP (clinicaltrials.gov) - Jan 3, 2013
P2, N=39, Recruiting, Sponsor: Lpath, Inc.
- ||||| New P2 trial: Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON) (clinicaltrials.gov) - Dec 27, 2012
P2, N=126, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| New P4 trial: BiobankII: Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis (clinicaltrials.gov) - Dec 20, 2012
P4, N=250, Recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
- New P4 trial: Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod Untersuchung der nat (EUDRACT) - Dec 3, 2012
P4, N=40, Ongoing, Sponsor: Charit
- ||||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
New P2 trial: Dose-finding Study of MT-1303 (clinicaltrials.gov) - Dec 3, 2012
P2, N=400, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- |||| phenoxodiol (NV06) / MEI
Trial completion: Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Oct 21, 2012
P1/2, N=65, Completed, Sponsor: MEI Pharma, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Enrollment open: STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) (clinicaltrials.gov) - Oct 17, 2012
P4, N=7000, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Enrollment open: EARLiMS: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (clinicaltrials.gov) - Oct 17, 2012
P4, N=434, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- New P4 trial: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS (clinicaltrials.gov) - Oct 16, 2012
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- ||||| fingolimod / Generic mfg.
New P4 trial: PASSOS: A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya (clinicaltrials.gov) - Oct 10, 2012
P4, N=100, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||| iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
Trial initiation date, Monotherapy: Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (clinicaltrials.gov) - Sep 16, 2012
P2, N=160, Recruiting, Sponsor: Lpath, Inc.
Not yet recruiting --> Recruiting Initiation date: Sep 2011 --> Aug 2012
- || Enrollment change: Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program (clinicaltrials.gov) - Sep 4, 2012
P=N/A, N=64, Completed, Sponsor: Novartis
Initiation date: Sep 2011 --> Aug 2012 N=1200 --> 64
- ||| Trial completion: Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program (clinicaltrials.gov) - Sep 4, 2012
P=N/A, N=64, Completed, Sponsor: Novartis
N=1200 --> 64 Enrolling by invitation --> Completed
- |||| Extavia (IFN-?-1b) / Novartis
Trial completion: EPOC: A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Sep 3, 2012
P4, N=1053, Completed, Sponsor: Novartis Pharmaceuticals
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- |||| iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
Enrollment open, Monotherapy: Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (clinicaltrials.gov) - Aug 28, 2012
P2, N=160, Recruiting, Sponsor: Lpath, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease (clinicaltrials.gov) - Aug 14, 2012
P1, N=24, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- |||||||||| Mayzent (siponimod) / Novartis
New P3 trial: Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) (clinicaltrials.gov) - Aug 13, 2012
P3, N=1530, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Enrollment open: MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (clinicaltrials.gov) - Aug 13, 2012
P4, N=2550, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- LX 2931 / Lexicon Pharma
Trial completion: A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 31, 2012
P1, N=10, Completed, Sponsor: Lexicon Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || fingolimod / Generic mfg.
Enrollment change: PASSAGE: Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies (clinicaltrials.gov) - Jul 23, 2012
P=N/A, N=3600, Recruiting, Sponsor: Novartis
Active, not recruiting --> Completed N=3000 --> 3600
- || fingolimod / Generic mfg.
New P2/3 trial: MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) (clinicaltrials.gov) - Jul 22, 2012
P2/3, N=88, Recruiting, Sponsor: Charite University, Berlin, Germany
- ||||| Zeposia (ozanimod) / BMS
New P2 trial: TOUCHSTONE: Efficacy and Safety Study of Ozanimod in Ulcerative Colitis (clinicaltrials.gov) - Jul 19, 2012
P2, N=180, Recruiting, Sponsor: Receptos, Inc.
- ||||| New P4 trial: MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (clinicaltrials.gov) - Jul 2, 2012
P4, N=2550, Recruiting, Sponsor: Novartis Pharmaceuticals
- Enrollment open: Exploratory Study to Assess Clinical Response to Gilenya (clinicaltrials.gov) - Jun 28, 2012
P=N/A, N=50, Recruiting, Sponsor: University of Southern California
N=3000 --> 3600 Not yet recruiting --> Recruiting
- ||| Zeposia (ozanimod) / BMS
Enrollment change: RADIANCE: Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients (clinicaltrials.gov) - Jun 26, 2012
P2, N=210, Active, not recruiting, Sponsor: Receptos, Inc.
Not yet recruiting --> Recruiting N=1110 --> 210
- ||||| Zeposia (ozanimod) / BMS
New P2 trial: RADIANCE: Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients (clinicaltrials.gov) - Jun 24, 2012
P2, N=210, Active, not recruiting, Sponsor: Receptos, Inc.
- || New P3 trial: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (clinicaltrials.gov) - Jun 19, 2012
P3, N=156, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| New P4 trial: PREFERMS: Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. (clinicaltrials.gov) - Jun 18, 2012
P4, N=852, Recruiting, Sponsor: Novartis Pharmaceuticals
- New P4 trial: ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon (clinicaltrials.gov) - Jun 14, 2012
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- ||| ceralifimod (ONO 4641) / Ono Pharma
Enrollment closed: DreaMS: Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - May 22, 2012
P2, N=343, Active, not recruiting, Sponsor: EMD Serono
N=1110 --> 210 Enrolling by invitation --> Active, not recruiting
- ||||| New P4 trial: STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) (clinicaltrials.gov) - Apr 23, 2012
P4, N=7000, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||| Ponvory (ponesimod) / Juvise Pharma, Vanda
Enrollment closed: Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Apr 17, 2012
P2, N=353, Active, not recruiting, Sponsor: Actelion
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- | New P4 trial, HEOR: A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 (clinicaltrials.gov) - Apr 12, 2012
P4, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
- | Mayzent (siponimod) / Novartis
New P1 trial: Pharmacokinetics of BAF312 in Patients With Hepatic Impairment (clinicaltrials.gov) - Mar 27, 2012
P1, N=48, Recruiting, Sponsor: Novartis Pharmaceuticals
- | Mayzent (siponimod) / Novartis
New P1 trial: Study to evaluate the effect of oral BAF312 on a monophasic oral contraceptive in healthy female volunteers (EUDRACT) - Feb 15, 2012
P1, N=24, Ongoing, Sponsor: Novartis Pharma Services AG
- ||||| New P4 trial, Patient reported outcomes: Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (clinicaltrials.gov) - Feb 14, 2012
P4, N=313, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- |||| ceralifimod (ONO 4641) / Ono Pharma
Trial completion: DreaMS: A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Feb 2, 2012
P2, N=407, Completed, Sponsor: Ono Pharma USA Inc
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| phenoxodiol (NV06) / MEI
Enrollment change: OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - Feb 1, 2012
P3, N=142, Completed, Sponsor: MEI Pharma, Inc.
Active, not recruiting --> Completed N=340 --> 142
- ||||||| phenoxodiol (NV06) / MEI
Trial completion: OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - Feb 1, 2012
P3, N=142, Completed, Sponsor: MEI Pharma, Inc.
N=340 --> 142 Active, not recruiting --> Completed
- | iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
Trial completion: Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors (clinicaltrials.gov) - Jan 26, 2012
P1, N=37, Completed, Sponsor: Lpath, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion, HEOR: Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients (clinicaltrials.gov) - Jan 18, 2012
P3, N=2417, Completed, Sponsor: Novartis
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| Tysabri (natalizumab) / Biogen, Royalty
New P4 trial: TOFIINGO: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (clinicaltrials.gov) - Dec 22, 2011
P4, N=158, Completed, Sponsor: Novartis Pharmaceuticals
- ||||| New P4 trial: EARLiMS: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (clinicaltrials.gov) - Dec 22, 2011
P4, N=434, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||||||||| New P3 trial: Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Dec 20, 2011
P3, N=161, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| New P4 trial: Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Dec 11, 2011
P4, N=178, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| Enrollment change: FREEDOMS II: Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 22, 2011
P3, N=632, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed N=1080 --> 632